Effect of Shipment, Storage, Anticoagulant, and Cell Separation on Lymphocyte Proliferation Assays for Human Immunodeficiency Virus-Infected Patients

ADRIANA WEINBERG,1* REBECCA A. BETENSKY,2 LI ZHANG,3 AND GRAHAM RAY1

University of Colorado School of Medicine, Denver, Colorado,1 and Harvard School of Public Health, Boston, Massachusetts2

Received 12 May 1998/Returned for modification 22 June 1998/Accepted 13 August 1998

Lymphocyte proliferation assays (LPA), which can provide important information regarding the immune reconstitution of human immunodeficiency virus (HIV)-infected patients on highly active antiretroviral therapy, frequently involve shipment of specimens to central laboratories. In this study, we examine the effect of stimulant, anticoagulant, cell separation, storage, and transportation on LPA results. LPA responses of whole blood and separated peripheral blood mononuclear cells (PBMC) to different stimulants (cytomegalovirus, varicella-zoster virus, candida and tetanus toxoid antigens, and phytohemagglutinin) were measured using fresh specimens shipped overnight and frozen specimens collected in heparin, acid citrate dextrose (ACD), and citrate cell preparation tubes (CPT) from 12 HIV-infected patients and uninfected controls. Odds ratios for positive LPA responses were significantly higher in separated PBMC than in whole blood from ACD- and heparin-anticoagulated samples obtained from HIV-infected patients and from ACD-anticoagulated samples from uninfected controls. On separated PBMC, positive responses were significantly more frequent in fresh specimens compared with overnight transportation for all antigens and compared with cryopreservation for the candida and tetanus antigens. In addition, viral antigen LPA responses were better preserved in frozen PBMC compared with specimens shipped overnight. CPT tubes yielded significantly more positive LPA results for all antigens, irrespective of the HIV patient status compared with ACD, but only for the candida and tetanus antigens and only in HIV-negative controls compared with heparin. Although HIV-infected patients had a significantly lower number of positive antigen-driven LPA responses compared with uninfected controls, most of the specimen processing variables had similar effects on HIV-positive and -negative samples. We conclude that LPA should be performed on site, whenever feasible, by using separated PBMC from fresh blood samples collected in either heparin or ACD. However, if on-site testing is not available, optimal transportation conditions should be established for specific antigens.

Human immunodeficiency virus (HIV) infection is associated with progressive loss of cell-mediated immune (CMI) responses that renders the host susceptible to opportunistic infections. The standard of care of patients with advanced AIDS has included prophylactic therapy for the most common opportunistic infections. The recent introduction of highly active antiretroviral therapy (HAART) has dramatically decreased the incidence of opportunistic infections in HIV-infected patients. The use of HAART has also resulted in predictable, potent, and durable suppression of HIV replication, elevation of the CD4 cell count, and increased survival of HIV-infected patients, including those with advanced disease (5). The extent of the immune reconstitution in these patients has been the object of several studies (1, 7). The findings showed a staggered improvement of immune function, including an increase in memory and naive CD4 cells, an increase in naive CD8 cells, a decrease in activated CD8 cells, and improvement of CD4 T-cell reactivity to recall antigens. In contrast, the Vβ repertoire remained abnormal (3), suggesting that in severely immunodepleted patients the immune reconstitution may not be complete. Furthermore, a minority of patients continue to experience opportunistic infections despite the increased number of CD4 cells (6). Functional CMI assays can provide prognostic information for HIV-infected patients (2). For patients on HAART, in addition to estimating the extent of immune reconstitution, pathogen-specific CMI assays might identify the individuals who will continue to require prophylactic therapy against specific agents.

Functional measurements of CMI responses commonly rely on antigen-specific lymphocyte proliferation assays (LPA). There is very little information on the effects of different methods of specimen collection, shipment, and processing on specific LPA results (4). However, this information is critically needed for the multicenter study designs currently used to acquire data on a large number of patients in a relatively short time. In these trials, specimens are frequently shipped fresh or after cryopreservation to central laboratories for special immunology studies such as LPA.

The objective of this study was to examine the effects of several variables—stimulant, anticoagulant, specimen storage and transportation, and cell separation—on LPA results for HIV-infected individuals.

MATERIALS AND METHODS

Study design. Informed consent was obtained from all study participants after the nature and possible consequences of this study had been fully explained to them. Five 8-ml tubes of blood were collected from HIV-infected patients and uninfected controls: two heparin tubes, two acid citrate dextrose (ACD) tubes, and one citrate cell preparation tube (CPT; Becton-Dickinson). One heparin tube and one ACD tube were processed on the day of collection. The remaining tubes were shipped overnight (Federal Express) and processed when received (after 24 h). Because CPTs are expensive, we did not use them for fresh cell assays, in which we did not expect a significant difference from heparin or ACD.
days of incubation at 37°C, wells were pulsed with 50 μM at 1:50 and 1:200 dilutions, respectively; candida antigen at 20 μM was prepared in our laboratory as previously described (11), candida antigen (Gree/ Laboratory), tetanus toxoid (Connaught Laboratory), and phytohemagglutinin (PHA; Sigma). Unstimulated controls were included. If there were insufficient cells for all 60 experimental conditions, then assays on cryopreserved cells were deleted in the following order: candida antigen, tetanus toxoid, VZV antigen, and CMV antigen.

**LPA on separated PBMC.** PBMC separated on Ficoll-Hypaque gradients (Sigma) or collected from CPTs were washed three times in phosphate-buffered saline, counted, and resuspended in RPMI 1640 medium (Gibco) with glutamine containing 10% human AB serum (Nabi) and 1% antibiotics (Gibco). PBMC, at 10^5/well, were added to triplicate wells containing the antigens (CMV and VZV at 1:50 and 1:200 dilutions, respectively; candida antigen at 20 μg/ml; and tetanus toxoid at 5 μg/ml), mitogen (PHA at 10 μg/ml), or no antigen (control). After 6 days of incubation at 37°C, wells were pulsed with 50 μCi of [3H]thymidine per well (1 μCi/ml; Amersham) for 6 h, harvested, and counted in a Beckman scintillation counter using Biosafe II scintillation liquid (Research Product International Corp.). The stimulation index (SI) was calculated by dividing the average counts per minute in stimulated wells by the average counts per minute in unstimulated wells. The antigen concentrations used in this study were standardized to yield an SI of ≥3 for immune individuals and an SI of <3 for naive individuals. By using PBMC obtained from five normal donors and serial dilutions of the stimulants, we chose the highest antigen concentration that did not have an inhibitory effect on the LPA of seropositive volunteers and did not stimulate the proliferation of PBMC from seronegative donors. A fraction of the blood collected in heparin and ACD, both from fresh samples and from overnight samples, was used for whole-blood LPA. PBMC separated from all tubes (including CPTs) were used in the LPA. A matched aliquot of these cells was cryopreserved and assayed by LPA at a later time. Each specimen was assayed by using the following antigens and mitogens: cytomegalovirus (CMV) and varicella-zoster virus (VZV) antigens prepared in our laboratory as previously described (11), candida antigen (Gree/ Laboratory), tetanus toxoid (Connaught Laboratory), and phytohemagglutinin (PHA; Sigma). Unstimulated controls were included. If there were insufficient cells for all 60 experimental conditions, then assays on cryopreserved cells were deleted in the following order: candida antigen, tetanus toxoid, VZV antigen, and CMV antigen.

**RESULTS**

**Demographics.** There were nine HIV-infected patients and three uninfected controls. The HIV-infected patients were males between 28 and 48 years of age (median, 41); seven were Caucasians, one was an African American, and one was Hispanic. Their CD4 counts varied from 164 to 403, with a mean and median of 238 and 235, respectively. Seven patients were on protease inhibitor-containing therapeutic regimens, one was on nucleoside analogue monotherapy, and one was on no therapy. Eight HIV-infected patients were seropositive for CMV, and one had unknown CMV status. All HIV-infected patients had prior chickenpox. Among the three uninfected controls, there were one male and two females, 40, 41, and 58 years of age. All were Caucasians and seronegative for both CMV and VZV. All study participants had been vaccinated against tetanus.

**Effect of stimulant.** The distribution of LPA-positive results (SI, ≥3) for each antigen and mitogen for HIV-infected patients and uninfected controls including all assay conditions is summarized in Table 1. Adjusting for all experimental factors, the odds ratio for a positive SI response to any antigen for HIV-positive versus HIV-negative individuals was 0.09, with a 95% confidence interval of 0.04 to 0.20. For the HIV-negative individuals, 20 to 30% of the assays had negative CMV, VZV, and candida results, and 66% of the tetanus-specific LPA had negative results. No negative assay results were observed for PHA. For the HIV-positive patients, 50 to 92% of the assays had negative results for CMV, VZV, candida, and tetanus. In contrast, only 6% of the assays had negative results for PHA. This shows that the proliferative response to PHA significantly differs from the antigen-induced proliferation. For this reason, for the analysis of the remaining variables (cell separation, transportation, and cryopreservation), we excluded the results of PHA-induced stimulation and used only the microbial antigen SI. The proportions of negative assays are slightly lower when restricting to separated peripheral blood mononuclear cell (PBMC) assays (Table 1). After adjusting for all specimen manipulations and anticoagulants, the odds ratios of a positive SI response for HIV-positive patients versus HIV-negative individuals were not significantly different among microbial antigens (P = 0.566).

**Effect of cell separation.** Whole-blood assays had a very small number of positive results after antigen stimulation: 30 (17%) of 176. In contrast, there were 152 positive results among 296 separated PBMC assays (51%) (Table 1). The odds of obtaining a positive response from separated PBMC were

| Cell type(s) | Response | SI of HIV-negative (HIV-positive) sample in response to: |
|--------------|----------|--------------------------------------------------------|
|              |          | CMV | Tetanus | VZV | Candida | PHA |
| Separated PBMC | Negative | 2 (22) | 12 (44) | 2 (36) | 2 (24) | 0 (0) |
|               | Positive | 21 (33) | 8 (7) | 18 (18) | 17 (30) | 22 (55) |
| Whole blood   | Negative | 7 (26) | 9 (32) | 7 (32) | 4 (29) | 0 (5) |
|               | Positive | 5 (6) | 3 (0) | 5 (0) | 8 (3) | 12 (27) |
| Both          | Negative | 9 (48) | 21 (76) | 9 (68) | 6 (53) | 0 (5) |
|               | Positive | 26 (39) | 11 (7) | 23 (18) | 25 (33) | 34 (82) |

* Positive, SI of ≥3; negative, SI of <3.
significantly higher than the odds of obtaining a positive response from whole-blood assays for HIV-infected patients for all microbial antigens and regardless of the anticoagulant or transportation (Table 2). This finding was also true for uninfected patient samples collected in ACD, regardless of transportation. The differences observed between separated PBMC and whole-blood samples collected in heparin from HIV-negative patients were marginally significant for fresh assays ($P = 0.071$) and not significant after overnight shipment ($P = 0.650$).

### Table 2. Odds ratios for a positive LPA response$^a$ in separated-PBMC versus whole-blood assays

| Anticoagulant | Storage | HIV positive OR | P   | HIV negative OR | P   |
|---------------|---------|----------------|-----|----------------|-----|
| Heparin       | Fresh   | 19.61          | <0.001 | 3.89          | 0.071 |
| Heparin       | Overnight | 6.99          | 0.002 | 1.39          | 0.650 |
| ACD           | Fresh   | 153.62         | <0.001 | 30.49         | <0.001 |
| ACD           | Overnight | 54.74         | <0.001 | 10.86         | <0.001 |

$^a$ SI, $\geq 3$.

The analysis of the effects of specimen storage and transportation, anticoagulant choice, and cell separation resulted in the same conclusions as those described above when a positive result was defined as an SI of $\geq 5$.

### Discussion

In this study, we showed that LPA results were greatly influenced by stimulant, cell transportation, storage, and cell separation. Separated PBMC yielded a significantly higher number of positive results than whole-blood assays, independently of anticoagulant and for all microbial antigens in HIV-infected patients. There was a similar effect in non-HIV-infected controls, but the differences were statistically significant only for ACD-anticoagulated samples. These results indicate that removal of the anticoagulant, erythrocytes, granulocytes, and/or patient plasma from the PBMC culture favors in vitro proliferation. Autologous serum has been used in LPA in previous studies (8) testing samples from healthy individuals, and it did not seem to inhibit proliferative responses. However, plasma from HIV-infected patients may contain cytokines or viral products that impair lymphocyte function. There was no difference between fresh and shipped samples in whole-blood assays (data not shown), but this was probably due to the low number of positive responses observed in whole-blood LPA. Although whole-blood assays are simpler and less time-consuming and therefore seem advantageous for the immunology laboratory work load, this method cannot be relied upon for CMI measurement in HIV-infected patients.

Fresh samples of separated PBMC yielded higher odds of obtaining positive LPA results for tetanus and candida compared with frozen PBMC and for all antigens compared with samples shipped overnight. This result was not surprising, and it probably reflects better preservation of cell viability and/or function in samples that were manipulated less. Frozen PBMC had a significantly higher number of positive LPA results than overnight specimens for the viral antigens and PHA (data not shown) but not for candida or tetanus.

There was no significant difference among anticoagulants in assays of fresh separated PBMC. Across all cell manipulations, heparin preserved only CMV responses significantly better than ACD. In contrast, CPT specimens had significantly higher odds ratios than ACD specimens in all patients and for all antigens. The difference between CPT and heparin was significant only in HIV-uninfected patients and only for tetanus.

### Table 3. Odds ratios for a positive LPA response in separated-PBMC assays

| Comparison                | OR ($P$ value) with stimulation by: |
|---------------------------|-------------------------------------|
|                            | CMV                   | Tetanus                | VZV                   | Candida                |
| Fresh vs ON$^a$            | 3.72 ($<0.001$)       | 3.72 ($<0.001$)       | 3.72 ($<0.001$)       | 3.72 ($<0.001$)       |
| Fresh vs Cryo$^b$          | 0.55 (0.466)          | 3.93 (0.020)           | 0.83 (0.796)          | 3.93 (0.020)          |
| ON vs Cryo                | 0.15 (0.016)          | 1.06 (0.918)           | 0.22 (0.030)          | 1.06 (0.918)          |
| Heparin vs ACD (HIV$^+$)  | 5.17 (0.008)          | 2.05 (0.098)           | 2.05 (0.098)          | 2.05 (0.098)          |
| Heparin vs ACD (HIV$^-$)  | 1.61 (0.565)          | 0.64 (0.475)           | 0.64 (0.475)          | 0.64 (0.475)          |
| CPT vs heparin (HIV$^+$)  | 0.61 (0.455)          | 1.55 (0.365)           | 1.55 (0.365)          | 1.55 (0.365)          |
| CPT vs heparin (HIV$^-$)  | 1.97 (0.443)          | 4.96 (0.020)           | 4.96 (0.020)          | 4.96 (0.020)          |
| CPT vs ACD                | 3.17 (0.008)          | 3.17 (0.008)           | 3.17 (0.008)          | 3.17 (0.008)          |

$^a$ ON, blood shipped overnight.

$^b$ Cryo, cryopreserved cells.
VZV, and candida antigens. Superior preservation of LPA responses in CPT tubes may be ascribed to separation of PBMC from erythrocytes and granulocytes during transport. Note that cell number or viability tested by trypan blue exclusion (data not shown) did not significantly vary with the type of anticoagulant or separation method.

The impact of different conditions on LPA results significantly differed among antigens and between mitogen and antigens. Mitogen responses were also better preserved than the antigen ones in HIV-infected patients. This finding is not surprising because mitogens activate a broad population of mononuclear cells and, unlike antigens, do not require processing, presentation, or functional memory T cells. Our results indicate that mitogen-stimulated LPA is not representative of the host immune status with respect to antimicrobial responses, nor can it substitute for antigen-specific proliferation when optimizing LPA conditions.

Overall, specimen handling affected LPA responses from HIV-infected patients and uninfected controls similarly. This observation suggests that the effect of specific factors on LPA responses in healthy individuals can be used to predict the effect of similar factors on specimens from HIV-infected patients.

In conclusion, when designing specimen processing for LPA as part of a multicenter study, preference should be given to on-site testing of fresh samples. If on-site testing is not a viable alternative, cryopreserved and overnight PBMC assays (particularly using CPT tubes) should be compared for the relevant antigens.

ACKNOWLEDGMENTS

We thank Myron J. Levin for critical review of the manuscript. This work was supported by the National Institute of Allergy and Infectious Diseases, the National Institute of Child Health and Human Development (NO1-HD-3-3162), and the Statistics and Data Analysis Center of the AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (N01-AI-95030).

REFERENCES

1. Autran, B., G. Carcelain, T. S. Li, C. Blanc, D. Mathez, R. Tubiana, C. Katlam, P. Debre, and J. Leibowitch. 1997. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277:112–116.

2. Bindels, P. J. E., A. Krol, M. Roos, J. Veenstra, A. R. van den Hoek, F. Miedema, and R. A. Coutinho. 1995. The predictive value of T cell function in vitro and pre-AIDS zidovudine use for survival after AIDS diagnosis in a cohort of homosexual men in Amsterdam. J. Infect. Dis. 172:97–104.

3. Connors, M., J. A. Kovacs, S. Krevat, J. C. Gea-Banacloche, M. C. Sneller, M. Flanigan, J. A. Metcalf, R. E. Walker, J. Falloon, M. Baseler, I. Feuerstein, H. Masur, and H. C. Lane. 1997. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat. Med. 3:533–540.

4. Fletcher, M. A., G. C. Baron, M. R. Ashman, M. A. Fischl, and N. G. Klimas. 1987. Use of whole blood methods in assessment of immune parameters in immunodeficiency states. Diagn. Clin. Immunol. 5:69–81.

5. Hammer, S. M., K. E. Squires, M. D. Hughes, J. M. Grimes, L. M. Demeter, J. S. Currier, J. J. Eron, J. E. Feinberg, H. H. Balfour, L. R. Dayton, J. A. Chodakewitz, and M. A. Fischl. 1997. A controlled study of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N. Engl. J. Med. 337:725–733.

6. Jacobson, M. A., M. Zegans, P. R. Pavan, J. J. O’Donnell, F. Sattler, N. Rao, S. Owens, and R. Pollard. 1997. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 349:1443–1445.

7. Kelleher, A. D., A. Carr, J. Zaunders, and D. A. Cooper. 1996. Alterations in the immune response of human immunodeficiency virus-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J. Infect. Dis. 173:321–329.

8. Levin, M. J., M. Murray, G. O. Zerbe, C. J. White, and A. R. Hayward. 1994. Immune responses of elderly persons 4 years after receiving a live attenuated varicella vaccine. J. Infect. Dis. 170:522–526.

9. Liang, K.-Y., and S. L. Zeger. 1986. Longitudinal data analysis using generalized linear models. Biometrika 73:13–22.

10. Neuhaus, J. M., and M. L. Lesperance. 1996. Estimation efficiency in a binary mixed-effects model setting. Biometrika 83:441–449.

11. Weinberg, A., T. Y. Basham, and T. C. Merigan. 1987. Regulation of the guinea pig immune function by interleukin-2: critical role of natural killer activity in acute HSV-2 genital infection. J. Immunol. 137:3310–3316.